[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 57 of about 57
1. Liu B, Yu HM, Huang J, Hsu W: Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis. Neoplasia; 2008 Sep;10(9):1004-13
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been well documented that two types of tumors, adenocarcinoma and adenocarcinoma with squamous metaplasia, develop in these mutants.
  • However, the molecular mechanism underlying the induction of squamous transdifferentiation remains largely unknown.
  • Here, we show that JNK/SAPK signaling plays an important role in Wnt-dependent mammary development and malignant transformation.
  • Strong elevations of JNK/SAPK signaling are associated with squamous metaplasia of the Wnt-induced adenocarcinoma.
  • Reconstitution of beta-catenin and JNK/SAPK signaling activities also promotes expression of the squamous cell marker in cultured epithelial cells.
  • Furthermore, a synergistic activation of these two pathways can be identified in the malignant squamous cells of human endometrial and lung cancers.
  • This is potentially a significant discovery in modern cancer therapy because of the effectiveness of an angiogenesis inhibitor, Avastin, for the treatment of adenocarcinoma, but not squamous cell carcinoma, in human lung cancers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Mar 15;14(6):650-4 [10733525.001]
  • [Cites] J Pathol. 2003 Nov;201(3):460-5 [14595758.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):32250-9 [10918063.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] J Cell Biol. 2001 Apr 30;153(3):555-68 [11331306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8668-73 [11447280.001]
  • [Cites] J Cell Biol. 2001 Dec 10;155(6):1055-64 [11739413.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Feb;282(2):L215-25 [11792626.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2073-84 [12183362.001]
  • [Cites] Development. 2002 Oct;129(20):4831-42 [12361974.001]
  • [Cites] Oncogene. 2002 Nov 14;21(52):7981-90 [12439748.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2892-901 [12456807.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1137-49 [12584256.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):791-7 [12791265.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3875-87 [12813461.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):593-7 [12841867.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):367-77 [12967557.001]
  • [Cites] J Biol. 2004;3(3):11 [15186480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31 [15300008.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell. 1988 Nov 18;55(4):619-25 [3180222.001]
  • [Cites] Genes Dev. 1994 Jan;8(1):118-30 [8288125.001]
  • [Cites] Nature. 1994 Jun 23;369(6482):669-71 [8208295.001]
  • [Cites] Genes Dev. 1994 Nov 15;8(22):2691-703 [7958926.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):798-800 [7997270.001]
  • [Cites] Genes Dev. 1995 May 1;9(9):1087-97 [7744250.001]
  • [Cites] Science. 1995 Jul 21;269(5222):403-7 [7618106.001]
  • [Cites] Cell. 1997 Jul 11;90(1):181-92 [9230313.001]
  • [Cites] Oncogene. 1997 Oct;15(18):2133-44 [9393971.001]
  • [Cites] Cell. 1998 Jul 10;94(1):109-18 [9674432.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4404-13 [9687508.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3526-8 [9721853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14717-22 [9843955.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3439-45 [9920888.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):741-56 [10330403.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):316-31 [15617677.001]
  • [Cites] Development. 2005 Apr;132(8):1995-2005 [15790973.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8615-20 [15941831.001]
  • [Cites] Dev Biol. 2005 Jul 1;283(1):226-39 [15907834.001]
  • [Cites] Cell Calcium. 2005 Sep-Oct;38(3-4):439-46 [16099039.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2187-95 [16051644.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):51-9 [16377174.001]
  • [Cites] Respirology. 2006 May;11(3):234-40 [16635080.001]
  • [Cites] Curr Biol. 2006 May 23;16(10):R378-85 [16713950.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Dev Cell. 2006 Nov;11(5):601-12 [17084354.001]
  • [Cites] Dev Biol. 2007 Jan 1;301(1):298-308 [17113065.001]
  • [Cites] PLoS One. 2006;1:e93 [17183725.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3172-84 [17496914.001]
  • [Cites] Dev Cell. 2007 Aug;13(2):268-82 [17681137.001]
  • [Cites] Development. 2007 Nov;134(21):3929-39 [17898001.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13132-9 [18316368.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):35247-54 [10575011.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):889-94 [10783160.001]
  • (PMID = 18714362.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106308; United States / NCI NIH HHS / CA / CA106308
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Wnt Proteins; 0 / Wnt1 Protein; 0 / Wnt1 protein, mouse; 0 / beta Catenin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2517646
  •  go-up   go-down


2. Hirschowitz L, Sen C, Murdoch J: Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia--a potential diagnostic pitfall. Diagn Pathol; 2007;2:40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia--a potential diagnostic pitfall.
  • BACKGROUND: Uterine or endocervical biopsies that contain endometrioid adenocarcinoma with widespread squamous metaplasia are usually of endometrial origin.
  • The presence of squamous metaplasia is said to be helpful in distinguishing endocervical from endometrial adenocarcinomas in small biopsy samples.
  • Biopsy of a friable lesion in the proximal endocervical canal revealed an endocervical adenocarcinoma of endometrioid type with widespread squamous metaplasia.
  • The latter feature initially raised the possible diagnosis of a primary endometrial adenocarcinoma.
  • However, immunohistochemical marker studies indicated a diagnosis of primary endocervical adenocarcinoma of endometrioid type and this was confirmed at hysterectomy.
  • CONCLUSION: Squamous differentiation is not well documented in endocervical adenocarcinomas of endometrioid type and, when widespread, may represent a diagnostic pitfall for pathologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):360-7 [12352184.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1137-42 [10619266.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):164-73 [12610091.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):8-15 [16462152.001]
  • [Cites] Am J Surg Pathol. 1980 Oct;4(5):481-9 [7435776.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Diagn Pathol. 2007;2:26 [17645802.001]
  • [Cites] Diagn Pathol. 2006;1:30 [16981999.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2293-302 [1913465.001]
  • (PMID = 17961245.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2116996
  •  go-up   go-down


3. Castillo CM, Ha CY, Gater DR, Grob BM, Klausner AP: Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia. J Spinal Cord Med; 2007;30(4):389-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia.
  • BACKGROUND/OBJECTIVE: To report a case of keratinizing squamous metaplasia of the bladder treated with radical cystectomy.
  • METHODS: Keratinizing squamous metaplasia of the bladder is a rare entity that can result from chronic irritative stimuli involving the bladder.
  • It is considered a premalignant condition associated with invasive squamous cell carcinoma.
  • A case report is presented describing the diagnosis and management of keratinizing squamous metaplasia of the bladder in a tetraplegic man with a chronic indwelling urinary catheter.
  • RESULTS: Radical cystectomy with an Indiana continent reservoir was performed after cystoscopy with biopsy confirmed keratinizing squamous metaplasia.
  • Final pathology revealed focal erosion and diffuse keratinizing squamous metaplasia of the bladder with prostatic adenocarcinoma as an incidental finding.
  • CONCLUSIONS: Patients with spinal cord injury who use indwelling catheters for bladder management are at higher risk of developing keratinizing squamous metaplasia.
  • Prophylactic cystectomy is sometimes warranted; however, observation and frequent cystoscopic surveillance to identify potential malignant transformation can be an alternative strategy.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Cystectomy / methods. Quadriplegia / complications. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 1994 Dec;37 Suppl:S39-40 [8613170.001]
  • [Cites] Arch Phys Med Rehabil. 1995 Aug;76(8):758-62 [7632132.001]
  • [Cites] J Urol. 1997 Jun;157(6):2115 [9146594.001]
  • [Cites] SCI Nurs. 1997 Sep;14(3):87-95 [9355615.001]
  • [Cites] J Clin Pathol. 1998 Aug;51(8):583-7 [9828815.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] World J Urol. 1999 Aug;17(4):211-8 [10460403.001]
  • [Cites] Urol Clin North Am. 2005 May;32(2):207-16 [15862618.001]
  • [Cites] J Urol. 2005 Nov;174(5):1729-36 [16217273.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):883-91 [16819332.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):457-61 [10668940.001]
  • [Cites] Spinal Cord. 2001 Nov;39(11):568-70 [11641805.001]
  • [Cites] BJU Int. 2002 Sep;90(4):386-90 [12175394.001]
  • [Cites] Eur Urol. 2002 Oct;42(4):350-5 [12361900.001]
  • [Cites] Eur Urol. 2002 Nov;42(5):469-74 [12429156.001]
  • [Cites] J Spinal Cord Med. 2003 Winter;26(4):335-8 [14992333.001]
  • [Cites] Qual Life Res. 2004 Feb;13(1):97-110 [15058792.001]
  • [Cites] Rehabil Nurs. 2004 Jul-Aug;29(4):122-6 [15222093.001]
  • [Cites] J Urol. 1967 Aug;98(2):206-8 [6046997.001]
  • [Cites] Urology. 1975 Dec;6(6):759-61 [1202729.001]
  • [Cites] J Urol. 1977 Dec;118(6):967-71 [926277.001]
  • [Cites] J Urol. 1979 Sep;122(3):317-21 [470001.001]
  • [Cites] S Afr Med J. 1980 Nov 1;58(18):725-8 [7423317.001]
  • [Cites] J Urol. 1985 Jun;133(6):1034-5 [3999203.001]
  • [Cites] J Urol. 1997 Jun;157(6):2112-4 [9146593.001]
  • (PMID = 17853664.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2031939
  •  go-up   go-down


Advertisement
4. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R: MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol; 2009 May;174(5):1940-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
  • Barrett's esophagus (BE)/Barrett's metaplasia (BM) is a recognized precursor of esophageal adenocarcinoma (EA) with an intermediary stage of dysplasia.
  • The low yield and high cost of endoscopic screening of patients with BE underscores the need for novel biomarkers, such as microRNA (miRNA), which have emerged as important players in neoplastic progression for risk assessment of developing dysplasia/adenocarcinoma.
  • Higher levels of miR-196a were observed in EA, BE, and dysplastic lesions compared with normal squamous mucosa, and in high-grade dysplasia compared with BE and low-grade dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Esophagus / pathology. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Calgranulin B / genetics. Calgranulin B / metabolism. Cornified Envelope Proline-Rich Proteins / genetics. Cornified Envelope Proline-Rich Proteins / metabolism. DNA Primers / chemistry. Disease Progression. Female. Humans. Keratin-5 / genetics. Keratin-5 / metabolism. Male. Metaplasia. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2007 May;21(5):912-6 [17330104.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4553-5 [17510380.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6667-78 [18663355.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19231-7 [11279051.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Mamm Genome. 2003 Feb;14(2):140-8 [12584609.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 [12916666.001]
  • [Cites] Cell Res. 2004 Feb;14(1):46-53 [15040889.001]
  • [Cites] World J Gastroenterol. 2004 Apr 15;10(8):1093-7 [15069705.001]
  • [Cites] Am J Surg. 1995 Jun;169(6):609-14 [7771626.001]
  • [Cites] Trends Biochem Sci. 1996 Apr;21(4):134-40 [8701470.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):671-4 [16319892.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 7;342(2):465-71 [16487489.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Science. 2006 Apr 7;312(5770):75-9 [16484454.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • (PMID = 19342367.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calgranulin B; 0 / Cornified Envelope Proline-Rich Proteins; 0 / DNA Primers; 0 / KRT5 protein, human; 0 / Keratin-5; 0 / MIRN196 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / SPRR2C protein, human
  • [Other-IDs] NLM/ PMC2671281
  •  go-up   go-down


5. Ormeci N, Savas B, Coban S, Palabiyikoğlu M, Ensari A, Kuzu I, Kursun N: The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma. Surg Endosc; 2008 Mar;22(3):693-700
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma.
  • BACKGROUND: Barrett's esophagus is a condition that is premalignant for adenocarcinoma of the esophagus and the esophagogastric junction.
  • Early detection of Barrett's metaplasia and dysplasia is very important to decrease the mortality and morbidity from esophageal adenocarcinoma cancer.
  • This study aimed to evaluate the effectiveness of methylene blue-targeted biopsies in the differential diagnosis of intestinal metaplasia, dysplasia, and superficial esophageal carcinoma.
  • However, there was no statistical difference between the two methods in the diagnosis of esophagitis or esophageal carcinoma (p > 0.05).
  • [MeSH-major] Barrett Esophagus / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagoscopy / methods. Methylene Blue. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Risk Assessment. Sensitivity and Specificity. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704887.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] T42P99266K / Methylene Blue
  •  go-up   go-down


6. Healy CF, Feeley L, Leen E, Walsh TN: Primary squamous cell carcinoma of the breast: value of positron emission tomography scanning in confirming the diagnosis. Clin Breast Cancer; 2006 Dec;7(5):413-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the breast: value of positron emission tomography scanning in confirming the diagnosis.
  • Pure primary squamous cell carcinoma of the breast is rare.
  • Controversy exists as to whether a pure form exists or whether described cases represent extreme squamous metaplasia within an adenocarcinoma.
  • We present a case of pure primary squamous cell carcinoma of the breast confirmed histopathologically with the absence of a distant primary tumor excluded using positron emission tomography.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239268.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Hannachi Sassi S, Dhouib R, Abbes I, Braham E, Mrad K, Driss M, Ben Hamida N, Ben Romdhane K: [Endometrial atypical complex hyperplasia with extensive squamous metaplasia: two cases]. Ann Pathol; 2008 Jun;28(3):233-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial atypical complex hyperplasia with extensive squamous metaplasia: two cases].
  • We report two cases of endometrial atypical complex hyperplasia with an extensive squamous hyperplasia occurring in two women aged 48 and 31 years old.
  • The histological study showed an increase in the gland to stroma ratio with a false crowding aspect due to an extensive area of squamous metaplasia; some metaplastic areas were centered by necrosis.
  • Histologic examination is necessary to confirm the diagnosis and to definitively rule out adenocarcinoma.
  • [MeSH-major] Endometrial Hyperplasia / pathology. Endometrium / pathology. Hyperplasia / pathology. Metaplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / pathology. Diagnosis, Differential. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Necrosis. Obesity / complications. Obesity / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706369.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, Wang J, Canto M, Eshleman JR, Montgomery EA, Maitra A: Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine; 2008 Dec;4(4):295-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.
  • Esophageal adenocarcinoma arises in the backdrop of Barrett metaplasia-dysplasia sequence, with the vast majority of patients presenting with late-stage malignancy.
  • Mesothelin expression was assessed in esophageal tissue microarrays encompassing the entire histological spectrum of Barrett-associated dysplasia and adenocarcinoma.
  • In contrast, normal squamous and cardiac mucosa, as well as noninvasive Barrett lesions, failed to label with mesothelin.
  • Mesothelin was expressed in the esophageal adenocarcinoma cell line JH-EsoAd1 but not in primary human esophageal epithelial cells.
  • Anti-mesothelin antibody-conjugated nanoparticles can be useful for the diagnosis and therapy of mesothelin-overexpressing esophageal adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] J Phys Chem B. 2007 Jun 28;111(25):6969-72 [17552555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):495-506 [9309400.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):381-9 [15725808.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):390-9 [15725809.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):752-61 [15696124.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1497-504 [16224217.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):417-28 [16415794.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):24-30 [16540726.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20 [16702385.001]
  • [Cites] Cancer Detect Prev. 2006;30(2):180-7 [16647225.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):20-4 [17044192.001]
  • [Cites] Gene Ther. 2007 Aug;14(16):1189-98 [17581599.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):490-7 [17532030.001]
  • [Cites] Chest. 2007 Oct;132(4):1239-46 [17646232.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3214-24 [18451147.001]
  • [Cites] J Immunother. 2000 Jul-Aug;23(4):473-9 [10916757.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):595-600 [12479219.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):238-43 [12966350.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Methods Enzymol. 2003;373:507-28 [14714424.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Nano Lett. 2007 Mar;7(3):761-5 [17288490.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):90-7 [8150545.001]
  • (PMID = 18691948.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA119397-04; United States / NCI NIH HHS / CA / R01 CA119397; United States / NCI NIH HHS / CA / R01 CA119397-04; United States / NCI NIH HHS / CA / R01CA119397
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS79893; NLM/ PMC2606904
  •  go-up   go-down


9. Smith AK, Hansel DE, Jones JS: Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology; 2008 May;71(5):915-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma.
  • OBJECTIVES: Cystitis cystica et glandularis (CCEG) and intestinal metaplasia (IM) have been suggested to represent precursors of bladder adenocarcinoma.
  • The records and imaging findings of patients with a pathologic diagnosis of florid CCEG and/or IM were reviewed for a concurrent or future diagnosis of bladder carcinoma or pelvic lipomatosis.
  • Of the 117 patients with CCEG, a subset was identified with concurrent mucinous adenocarcinoma (n = 1; <1%), squamous cell carcinoma (n = 4; 3%), or urothelial carcinoma (n = 34; 29%) at diagnosis.
  • Pure IM was identified concurrently with adenocarcinoma in 2 (10%), urothelial carcinoma in 4 (21%), and urothelial carcinoma with glandular differentiation in 1 (5%) of 19 patients.
  • Although IM can be associated with a concurrent diagnosis of carcinoma, we found no evidence that it increases the future risk of malignancy and our findings do not support a recommendation for surveillance cystoscopy in such patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Metaplasia / complications. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455631.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Allameh A, Rasmi Y, Nasseri-Moghaddam S, Tavangar SM, Sharifi R, Sadreddini M: Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects. Cancer Epidemiol; 2009 Jul;33(1):79-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
  • SUBJECTS: Formalin-fixed, paraffin-embedded esophageal specimens (n=87) from patients with gastroesophageal reflux disease (GERD), Barrett's metaplasia, adenocarcinoma (ADC) and squamous cells carcinoma (SCC) were collected based on their pathological diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


11. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KM, Berg KD: Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):24-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
  • The authors identified upregulation of Claudins 3, 4, and 7 in gastric adenocarcinoma using Affymetrix U-133 oligonucleotide microarrays and immunohistochemistry (IHC).
  • While normal gastric mucosa lacked Claudin 3, 4, and 7 expression, intestinal metaplasia and dysplasia showed these proteins.
  • The authors hypothesized that Claudins would be similarly overexpressed in Barrett's esophagus (BE)/adenocarcinoma.
  • IHC validation was performed using tissue microarrays constructed from esophageal resection specimens containing squamous (44 cases), gastric (40 cases), and non-dysplastic BE (16 cases), low-grade and high-grade dysplasia (16 and 26 cases), adenocarcinoma (58 cases), and nodal metastases (27 cases).
  • By IHC, Claudin 3 expression was 1+ in most (>95%) normal squamous or gastric tissues and 2+ to 4+ in more than 80% of high-grade dysplasia, adenocarcinoma, and metastases specimens.
  • Claudin 4 protein expression was 2+ or less in most squamous and gastric mucosa (>90%) but 3+ or 4+ in BE, low- and high-grade dysplasia, adenocarcinoma, and metastases specimens (>90%).
  • Claudin 7 expression was minimal in squamous and gastric mucosa but strong (3+ to 4+) in BE and low-grade dysplasia.
  • In high-grade dysplasia, adenocarcinoma, and metastases, Claudin 7 was less intense, with 60% to 70% staining 3+ or 4+ and 30% to 40% staining weakly (1+ or 2+).
  • The findings suggest that alterations in Claudin proteins are an early event in tumorigenesis and may provide targets for diagnosis and directed therapy for esophageal adenocarcinoma and its precursors.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540726.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


12. Bitar M, Mandel E, Kirschenbaum AM, Unger PD: Urinary bladder adenocarcinoma arising in a spina bifida patient. Ann Diagn Pathol; 2007 Dec;11(6):453-6
MedlinePlus Health Information. consumer health - Spina Bifida.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder adenocarcinoma arising in a spina bifida patient.
  • Intestinal metaplasia of the urothelium indicates the presence of intestinal-type goblet cells and was generally observed to coexist with or to precede the diagnosis of bladder adenocarcinomas.
  • Controversy continues of whether intestinal metaplasia is an acquired precancerous lesion, secondary to different insults to the urothelium, or a concomitant lesion in glandular carcinogenesis.
  • Patients with neurogenic bladders are particularly at risk for developing bladder cancer, mostly squamous cell carcinoma and rarely adenocarcinoma.
  • Spina bifida is a congenital developmental abnormality that may result in neurogenic bladder.
  • There is only one previously reported case of urothelial carcinoma with associated squamous metaplasia of the bladder occurring in a spina bifida patient.
  • We report the first case of bladder adenocarcinoma associated with intestinal metaplasia occurring in a spina bifida occulta patient.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Adenocarcinoma, Mucinous / pathology. Spinal Dysraphism / complications. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Immunohistochemistry. Intestines / pathology. Male. Metaplasia. Middle Aged. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Urinary Bladder, Neurogenic / complications

  • Genetic Alliance. consumer health - Spina bifida.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022132.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Nash JW, Bhardwaj A, Wen P, Frankel WL: Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):59-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study.
  • Maspin expression has been documented using immunohistochemical studies in pancreatic adenocarcinoma and high-grade intraductal dysplasia.
  • Immunohistochemistry was performed on tissue microarrays made from 72 cases of pancreatic ductal adenocarcinoma and 24 cases of chronic pancreatitis.
  • Diffuse and intense (3 +) staining was present in ducts with squamous metaplasia (3 cases).
  • Maspin may be helpful in differentiating ductal adenocarcinoma from chronic pancreatitis, once squamous metaplasia is ruled out.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536309.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


14. Long KB, Hornick JL: SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol; 2009 Dec;40(12):1768-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract.
  • SOX2 is a high-mobility group box embryonic stem cell transcription factor that is expressed in the developing foregut and normal gastric epithelium and is downregulated in intestinal metaplasia of the stomach and esophagus.
  • In addition, SOX2 colocalizes with p63 in the basal layer and plays a critical role in the maintenance of the stratified squamous epithelium of the esophagus.
  • SOX2 expression in squamous cell carcinomas of the gastrointestinal tract has not been previously evaluated.
  • The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2.
  • In total, 93 tumors were evaluated: 26 esophageal squamous cell carcinomas, 23 esophageal adenocarcinomas, 21 squamous cell carcinomas of the anal canal, and 23 rectal adenocarcinomas.
  • SOX2 was expressed in 81% of esophageal squamous cell carcinomas and 91% of anal canal squamous cell carcinomas, compared to 13% and 17% of esophageal and rectal adenocarcinomas, respectively. p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.
  • Cytokeratin 5/6 was expressed in most esophageal and anal canal squamous cell carcinomas, but was also positive in 43% of esophageal adenocarcinomas and 13% of rectal adenocarcinomas.
  • In summary, SOX2 is preferentially expressed in squamous cell carcinomas of the esophagus and anal canal compared to adenocarcinomas from these sites.
  • SOX2 may be useful in an immunohistochemical panel to differentiate between squamous cell carcinomas and adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Gastrointestinal Neoplasms / metabolism. SOXB1 Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Diagnosis, Differential. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CKAP4 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  •  go-up   go-down


15. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Mean patient age at diagnosis was 72 years (range 58 to 93 y).
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Multiple histologic patterns were observed including dissection of the stroma by mucin pools 15/15 (100%), villous features 7/15 (47%), necrosis 2/15 (13.3%), signet ring cells 3/15 (20%), perineural invasion 1/15 (6.7%), focal squamous differentiation 1/15 (6.7%), and a granulomatous inflammatory response 1/15 (6.7%).
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


16. Ong CA, Lao-Sirieix P, Fitzgerald RC: Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol; 2010 Dec 7;16(45):5669-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
  • Barrett's esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium.
  • It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Methods Inf Med. 2001 Mar;40(1):1-5 [11310153.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):859-66 [11565671.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 1;30(7):e28 [11917034.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Dis Esophagus. 2003;16(1):17-23 [12581249.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1439-44 [14602436.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):313-7 [14645692.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Dis Esophagus. 2004;17(2):136-40 [15230726.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9523-7 [1946366.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1030-4 [9067264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2284-9 [9122186.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1755-63 [9676852.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):351-8 [15688381.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Drug Discov Today. 2005 Jul 15;10(14):965-76 [16023055.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):387-91 [16106245.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):955-61 [16153457.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):264-8 [16477636.001]
  • [Cites] BMC Cancer. 2006;6:134 [16712734.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3789-98 [16785472.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Scand J Gastroenterol. 2007 Jun;42(6):682-8 [17505989.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3602-9 [17896157.001]
  • [Cites] Scand J Gastroenterol. 2007 Nov;42(11):1271-4 [17852872.001]
  • [Cites] Dis Esophagus. 2008;21(2):97-102 [18269642.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Cancer. 2008 May 15;112(10):2173-80 [18348304.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] BMC Cancer. 2008;8:254 [18778486.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3459-70 [18825457.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8279-87 [19088045.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):58-65 [18820669.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] BMJ. 2009;338:b604 [19336487.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1093-6 [19417749.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] BMJ. 2009;338:b606 [19502216.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6192-200 [19789312.001]
  • [Cites] Am J Gastroenterol. 2009 Oct;104(10):2588-94 [19623166.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):330-7 [20028767.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):317-26 [19997771.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Am J Med. 2010 May;123(5):462-7 [20399324.001]
  • [Cites] Surg Endosc. 2010 May;24(5):1144-50 [19997751.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1523-30 [20461069.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):1995-2004.e15 [20621683.001]
  • [Cites] Nat Rev Genet. 2010 Mar;11(3):191-203 [20125086.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2738-41 [15102678.001]
  • [Cites] BMJ. 2009;338:b375 [19237405.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):865-70 [10732760.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):1933-7 [10928129.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • (PMID = 21128316.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2997982
  •  go-up   go-down


17. Sanati S, Huettner P, Ylagan LR: Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol; 2010 Jan;29(1):79-87
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens.
  • Minichromosome maintenance and topoisomerase II alpha proteins play an important role in the regulation of eukaryotic DNA replication, and are overexpressed in a number of dysplastic and malignant tissues.
  • Our purpose was to evaluate the sensitivity, specificity, and predictive value of ProExC in dysplastic squamous and glandular lesions of the cervix.
  • Nine low-grade squamous intraepithelial lesion, 35 high-grade squamous intraepithelial lesion, 23 squamous metaplasia, and 14 adenocarcinoma in situ specimens were retrieved from our hospital files.
  • ProExC had sensitivity, specificity, and positive and negative predictive value of 89%, 100%, 100%, and 82%, respectively, for distinguishing high-grade squamous intraepithelial lesion from squamous metaplasia, and 93%, 100%, 100%, and 98%, respectively, for distinguishing adenocarcinoma in situ from reactive benign endocervix.
  • ProExC is a valuable marker for distinguishing dysplastic squamous and endocervical lesions of the cervix from squamous metaplasia in histologic sections.
  • ProExC may eventually be used in conjunction with morphologic and human papillomavirus evaluation for better classification of indeterminate cervical lesions in Papanicolaou smears.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Immunoenzyme Techniques. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952938.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


18. Staats PN, Clement PB, Young RH: Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2007 Oct;31(10):1490-501
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
  • Vaginal adenocarcinoma is the second most common primary cancer of the vagina, yet there has been very little study of most subtypes other than clear cell carcinoma.
  • We reviewed 18 cases of primary vaginal endometrioid adenocarcinoma, in our experience the second most common subtype.
  • On microscopic examination, each of the tumors had a pure or predominant component of typical endometrioid adenocarcinoma.
  • There was squamous metaplasia in 4 cases, mucinous metaplasia in 4, and prominent nonvillous papillae in 2.
  • Other subtypes of adenocarcinoma (such as serous when the tumor has a papillary pattern) and atypical forms of endometriosis, including polypoid endometriosis, are the most common other differential diagnostic considerations.
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895749.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Cantu de Leon D, Perez Montiel D, Tabarez A, Martinez RM, Cetina L: Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors. World J Surg Oncol; 2009;7:20
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.
  • CASE PRESENTATION: We report a synchronic fallopian tube adenocarcinoma and a verrucous cervical cancer.
  • A 85-year-old woman with postmenopausal genital hemorrhage, endometrial biopsy was reported as squamous metaplasia, an exploratory laparotomy was performed finding a tubal tumor diagnosed as adenocarcinoma, a staging procedure was performed.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2007 Apr;114(4):425-9 [17309544.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(6):501-2 [18179146.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):29-35 [16445606.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):765-9 [11076434.001]
  • [Cites] Pathol Res Pract. 1998;194(10):713-20 [9820868.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Ugeskr Laeger. 1993 Feb 22;155(8):565-6 [8451794.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1984 Apr;36(4):617-22 [6715942.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1050-4 [14674078.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(1):73-5 [12691323.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Jun;26(3):189-92 [10932980.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Arch Gynecol Obstet. 2008 Jun;277(6):557-62 [18066567.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6C):4491-4 [18214065.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • (PMID = 19222847.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2649116
  •  go-up   go-down


20. Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ: Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res; 2006 Oct;135(2):337-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
  • INTRODUCTION: Barrett's esophagus and adenocarcinoma of the esophagus are related to long-standing duodeno-gastroesophageal reflux.
  • The development of an animal model in which Barrett's esophagus and/or carcinoma is induced by duodeno-(gastro-)esophageal reflux could provide better understanding of the pathogenesis of the metaplasia-dysplasia-carcinoma sequence and would create the possibility of investigating new treatment strategies for this aggressive disease.
  • Sequential morphological changes (i.e., esophagitis, intestinal metaplasia, dysplasia, and carcinoma) were studied after 4, 6, and 12 months.
  • In four animals a large, well-differentiated, mucinous tumor without malignant characteristics was observed.
  • In these animals, extensive esophagitis with squamous cell hyperplasia was found.
  • Finally, in seven animals a mucinous tumor with cytologic characteristics of a well-differentiated mucinous adenocarcinoma was found without infiltrative growth.
  • Although they showed cytological characteristics of malignancy, histopathologic evaluation was more suggestive of a reactive mucous producing lesion fitting the diagnosis "esophagitis cystica profunda."
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Disease Models, Animal. Esophageal Neoplasms / pathology. Gastrointestinal Tract / surgery


21. Ponsot P: [Barrett's oesophagus: endoscopic diagnosis and follow-up]. Ann Chir; 2006 Jan;131(1):3-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's oesophagus: endoscopic diagnosis and follow-up].
  • Barrett's oesophagus (BO), or replacement of the squamous mucosa by a specialized intestinal metaplasia due to gastro-oesophageal reflux disease (GORD), predisposes to adenocarcinoma.
  • Macroscopic diagnosis of BO is sometimes difficult and, in case of doubt, endoscopy should be redone after a period of efficient anti-secretory treatment.
  • Diagnosis of BO is histological and should be confirmed by biopsies.
  • The incidence of adenocarcinoma is globally estimated at 0.5% patient by year of follow-up, and exists for both short and long BO.
  • Due to this low incidence, screening for BO is only justified in patients at high risk for adenocarcinoma (male gender, age > 50 ans, old GORD in a young patient).
  • Low-grade dysplasia (LGD) then high-grade dysplasia (HGD) precedes adenocarcinoma.
  • Histological diagnosis of LGD is difficult: the main cause of confusion is inflammation so diagnosis of LGD must be confirmed after a 3-month high-dose anti-secretory treatment.
  • Diagnosis of HGD is easier but multiple biopsies are needed to determine the focal or multifocal disposition of HGD.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / diagnosis. Endoscopy, Gastrointestinal. Esophageal Neoplasms / etiology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Gastroesophageal Reflux / complications. Humans. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376849.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


22. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Similarly, HPV-associated invasive squamous carcinomas are p16-positive, whereas the more common non-HPV-associated neoplasms are largely negative or focally positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


23. Gaddam S, Sharma P: Advances in endoscopic diagnosis and treatment of Barrett's esophagus. J Dig Dis; 2010 Dec;11(6):323-33
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in endoscopic diagnosis and treatment of Barrett's esophagus.
  • Barrett's esophagus (BE) is defined as abnormal specialized columnar metaplasia with intestinalization in place of the normal squamous esophageal epithelium.
  • Patients with high grade dysplasia (HGD) and early cancer have a high rate of progression to invasive adenocarcinoma and traditionally these patients were treated with esophagectomy.
  • [MeSH-major] Adenocarcinoma. Barrett Esophagus. Endoscopy, Digestive System / trends. Esophageal Neoplasms

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21091894.001).
  • [ISSN] 1751-2980
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


24. Saad RS, Takei H, Liu YL, Silverman JE, Lipscomb JT, Ruiz B: Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol; 2006 Jan-Feb;50(1):48-54
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears.
  • OBJECTIVE: To evaluate the significance of a diagnosis of atypical glandular cells, favor endometrial origin (AGC-EM), using cytohistologic correlation.
  • STUDY DESIGN: A retrospective search identified 90 cervicovaginal smears (vaginal pool) with a diagnosis of AGC-EM, in 2 tertiary care medical centers between January 1998 and December 2002.
  • Among the patients who underwent biopsy, 22 (40%) had a clinically significant lesion, including 10 (18%) endometrial adenocarcinomas, 8 (15%) endometrial hyperplasias and 4 (7%) high grade squamous intraepithelial lesion/squamous cell carcinoma, nonkeratinizing type.
  • The remaining 33 patients had benign histology, including benign endometrium, endometrial polyp, tubal metaplasia, cystic endometrial atrophy and cervical microglandular hyperplasia.
  • Of the patients with cytologic follow-up, 2 had Pap smears showing atypical squamous cells of undetermined significance, while the remainder had negative results.
  • CONCLUSION: In our study population, 40% (22 of 55) of women who underwent biopsy following a diagnosis of AGC-EM had significant uterine lesions, with the majority of the lesions endometrial in origin.
  • Patients with a diagnosis of AGC-EM, especially those > 50, should be followed closely, and endometrial sampling should be included in their initial workup.
  • [MeSH-major] Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Endometrium / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Metaplasia / diagnosis. Metaplasia / pathology. Middle Aged. Polyps / diagnosis. Polyps / pathology. Retrospective Studies


25. Dias Pereira A, Suspiro A, Chaves P: Cancer risk in Barrett's oesophagus. Eur J Gastroenterol Hepatol; 2007 Nov;19(11):915-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • )Barrett's oesophagus results from the replacement of the normal squamous lining of the oesophagus by a columnar epithelium.
  • It is the sole known premalignant condition for oesophageal adenocarcinoma.
  • The prerequisite of the presence of intestinal metaplasia for the diagnosis of Barrett's oesophagus, although widely accepted, is questioned by some authors.
  • How adenocarcinoma incidence is influenced by requiring or not intestinal metaplasia for Barrett's oesophagus diagnosis is unknown.
  • Data on adenocarcinoma incidence in short segments (<3 cm) are very scarce, but it is believed to be lower than in long segments.
  • Frequently, therapeutic intervention is performed when high-grade dysplasia is diagnosed, preventing progression to adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / pathology. Esophagoscopy. Humans. Incidence. Intestines / pathology. Metaplasia. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049157.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer; 2006 Nov 15;107(10):2417-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A higher frequency of adenocarcinoma has been reported in patients with COPD.
  • METHOD: An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV(1)]: 53 +/- 19% [mean +/- SD]) patients with a history of smoking (53 +/- 34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC).
  • RESULTS.: In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia (SM), and 8 dysplasia (Dy).
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Chaperonin 10 / metabolism. Chaperonin 60 / metabolism. Lung Neoplasms / diagnosis. Pulmonary Disease, Chronic Obstructive / complications. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Blotting, Western. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Disease Progression. Down-Regulation. Humans. Middle Aged. Prognosis. Respiratory Mucosa / pathology


27. Maezato K, Nishimaki T, Oshiro M, Yamashiro T, Sasaki H, Sashida Y: Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today; 2007;37(12):1096-101
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumor was signet-ring cell carcinoma covered with normal squamous epithelium.
  • However, the most superficial part of the tumor center contained a region of Barrett's mucosa with incomplete-type intestinal metaplasia and a well-differentiated adenocarcinoma component with goblet cells.
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Esophagectomy. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030574.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Bendic A, Bozic M, Durdov MG: Metaplastic breast carcinoma with melanocytic differentiation. Pathol Int; 2009 Sep;59(9):676-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metaplastic carcinoma of the breast is a rare heterogeneous malignancy, accounting for <1% of all invasive breast carcinomas, in which adenocarcinoma is found to coexist with an admixture of spindle, squamous, chondroid or bone-forming neoplastic cells.
  • After histological and immunohistochemical examination of the resected tumor mass, initial diagnosis was collision tumor: ductal invasive carcinoma and metastatic melanoma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Melanocytes / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Mastectomy, Segmental. Metaplasia. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712138.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Basseri B, Conklin JL, Mertens RB, Lo SK, Bellack GS, Shaye OA: Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature. Dis Esophagus; 2009;22(4):E1-5
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophageal and supraesophageal symptoms are commonly associated with inlet patch, while esophageal adenocarcinoma rarely complicates it.
  • Laryngeal adenocarcinoma associated with inlet patch is not described in the literature.
  • Biopsies showed columnar mucosa (predominantly gastric cardiac/fundic type) consistent with inlet patch, with focal intestinal metaplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473208.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


30. Punia RS, Arya S, Mohan H, Duseja A, Bal A: Spectrum of clinico-pathological changes in Barrett oesophagus. J Assoc Physicians India; 2006 Mar;54:187-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Barrett oesophagus is replacement of squamous epithelium to specialised intestinal metaplasia.
  • It is associated with an increased risk for adenocarcinoma which develops through dysplasia.
  • On histology examination, in 6 cases, squamous epithelium was replaced by intestinal epithelium containing goblet cells and in 7 cases it was replaced by gastric epithelium.
  • Associated dysplasia was not seen in any of the case, while one case showed associated adenocarcinoma.
  • There is a paucity of patients with pure dysplasia in Barrett metaplasia.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy. Esophagoscopy. Female. Humans. India. Male. Metaplasia. Middle Aged. Retrospective Studies. Sex Factors. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800342.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


31. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z: DEK overexpression in uterine cervical cancers. Pathol Int; 2008 Jun;58(6):378-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DEK protein expression was studied in 253 cervical lesions, including 30 non-neoplastic cervix with or without squamous metaplasia, 64 cervical intra-epithelial neoplasias (CIN; CIN-1, n = 28; CIN-2, n = 17; CIN-3, n = 19), 102 squamous cell carcinomas (SCC), 51 adenocarcinomas, and six adenosquamous cell carcinomas (adenoSCC) on immunohistochemistry.
  • In summary, DEK plays an important role in the carcinogenesis of cervical cancers, and can be helpful for early diagnosis, and is a potential therapeutic target.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Chromosomal Proteins, Non-Histone / metabolism. Oncogene Proteins / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477217.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA, Viral; 0 / Dek protein, human; 0 / Oncogene Proteins
  •  go-up   go-down


32. Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon DK, Johnson TD, Appelman H, Beer DG, Wang TD: Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology; 2010 Nov;139(5):1472-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Peptide selection was performed using phage display by removing nonspecific binders using Q-hTERT (intestinal metaplasia) cells and achieving specific binding against OE33 (esophageal adenocarcinoma) cells.
  • On esophageal specimens (n = 12), the fluorescence intensity (mean ± SEM) in 1-mm intervals classified histologically as squamous (n = 145), intestinal metaplasia (n = 83), dysplasia (n = 61), and gastric mucosa (n = 69) was 46.5 ± 1.6, 62.3 ± 5.8, 100.0 ± 9.0, and 42.4 ± 3.0 arb units, respectively.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Med. 2002 Oct 15;113(6):499-505 [12427500.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):406-14 [11832455.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Int J Pept Protein Res. 1990 Mar;35(3):161-214 [2191922.001]
  • [Cites] Science. 1990 Jul 27;249(4967):386-90 [1696028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82 [2201029.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5907-16 [15994969.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):867-72 [16981102.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6049-55 [17947467.001]
  • [Cites] Nat Med. 2008 Apr;14(4):454-8 [18345013.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1577-85 [18834215.001]
  • [Cites] Leukemia. 2009 Feb;23(2):235-44 [19151784.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):105-19 [18975117.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Mol Biosyst. 2009 Nov;5(11):1279-91 [19823742.001]
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):94-100 [19864239.001]
  • [Cites] N Engl J Med. 2009 Dec 24;361(26):2548-56 [20032324.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):435-46 [19852961.001]
  • [Cites] J Natl Cancer Inst. 2010 Feb 24;102(4):271-4 [20075370.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):828-33.e1 [20096697.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1341-7 [10728696.001]
  • [Cites] Cell Growth Differ. 2001 Apr;12(4):201-10 [11331249.001]
  • [CommentIn] Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):3 [21265056.001]
  • (PMID = 20637198.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA163059; United States / NCI NIH HHS / CA / U54 CA163059-01; United States / NCI NIH HHS / CA / U54 CA13642; United States / NCI NIH HHS / CA / U54 CA136429; United States / NCI NIH HHS / CA / U54 CA136429-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / Carrier Proteins
  • [Other-IDs] NLM/ NIHMS365874; NLM/ PMC3319360
  •  go-up   go-down


33. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


34. Micev M, Cosić-Micev M: [Pathology and pathobiology of the oesophageal carcinoma]. Acta Chir Iugosl; 2010;57(2):15-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Identification of dysplasia in mucosal biopsies is the most reliable pathologic indicator of an increased risk of development of squamous cell carcinoma and passes through the sequence of chronic esophagitis, low-grade and high-grade dysplasia and invasive carcinoma.
  • Although Barrett's esophagus is a precursor to esophageal adenocarcinoma and have a well described sequence of carcinogenesis: the Barrett's metaplasia-dysplasia-adenocarcinoma sequence, not all patients with this disorder require intensive surveillance.
  • More studies are needed to define other early nonmorphologic biomarkers for risk of squamous cell carcinoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Barrett Esophagus / complications. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Humans

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954310.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  •  go-up   go-down


35. Jaquet Y, Pilloud R, Grosjean P, Radu A, Monnier P: Extended endoscopic mucosal resection in the esophagus and hypopharynx: a new rigid device. Eur Arch Otorhinolaryngol; 2007 Jan;264(1):57-62
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a new device allowing for the diagnosis and treatment of extended superficial lesions of the esophagus and hypopharynx such as early squamous cell carcinoma, intestinal metaplasia with high grade intraepithelial neoplasia or early adenocarcinoma arising in Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Endoscopy / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / surgery. Minimally Invasive Surgical Procedures / instrumentation
  • [MeSH-minor] Barrett Esophagus / pathology. Barrett Esophagus / surgery. Early Diagnosis. Equipment Design. Humans. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043858.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Kimura W: Pancreatic lithiasis and intraductal papillary-mucinous neoplasm with special reference to the pathogenesis of lithiasis. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):776-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic lithiasis may be related to squamous cell metaplasia.
  • The relation between mucinous metaplasia and stone formation is slight and, therefore, there may be only a weak correlation between IPMN and pancreatic stones.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Lithiasis / diagnosis. Pancreas. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pancreatitis, Chronic / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779665.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


37. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Confusion regarding the diagnosis of Barrett's oesophagus exists because of a false dogma that cardiac mucosa is normally present in the gastro-oesophageal junctional region.
  • Recent data indicate that the only normal epithelia in the oesophagus and proximal stomach are squamous epithelium and gastric oxyntic mucosa.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • Histopathological precision cannot be matched by any other modality and can convert the confusion that exists regarding diagnosis of Barrett's oesophagus to complete lucidity in a manner that is simple, accurate, and reproducible.
  • [MeSH-minor] Esophagogastric Junction / pathology. Humans. Metaplasia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


38. Bewtra C, Xie QM, Hunter WJ, Jurgensen W: Ichthyosis uteri: a case report and review of the literature. Arch Pathol Lab Med; 2005 May;129(5):e124-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous metaplasia of endometrium is mostly manifested by morules or nodules of benign nonkeratinizing squamous cells intimately mixed with benign or malignant endometrial glands.
  • It has been described with low-grade adenocarcinoma of the endometrium, as well as with various benign conditions, including hyperplasia, chronic endometritis, and endometrial polyps.
  • However, extensive plaquelike, keratinizing squamous change is distinctly uncommon.
  • To our knowledge, we describe the first case of extensive benign squamous keratinization with underlying endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ichthyosis / diagnosis. Uterus / pathology

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859657.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


39. Arafa M, Boniver J, Delvenne P: Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):422-32
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For these reasons, a continuous effort is still needed to discover surrogate markers, which could support the final diagnosis.
  • Archival biopsies of normal ectocervical and endocervical tissues, squamous metaplasia, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, adenocarcinoma in situ, and adenocarcinoma were retrieved to perform a tissue microarray (TMA).
  • In situ hybridization signals suggesting integrated viral physical status predominated in CIN II/III, squamous cell carcinoma, and glandular (pre) neoplastic lesions.
  • Involucrin positivity was better appreciated in well-differentiated diagnostic entities (ectocervix, mature metaplasia, and CIN I).

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18542030.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Theisen J, Feith M, Stein HJ, Siewert JR: Management of early esophageal cancer. Adv Surg; 2007;41:229-39
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In early esophageal cancer, squamous cell cancer and early adenocarcinoma must be managed differently because they have different origins, pathogenesis. and clinical characteristics.
  • Instead, an individualized strategy should be based on the depth of tumor infiltration into the mucosa or submucosa, the presence or absence of lymph node metastases, the multicentricity of tumor growth, the length of the segment of intestinal metaplasia, and comorbidities of the patient.
  • Endoscopic mucosectomy may be sufficient in a subset of patients who have m1 or m2 squamous cell carcinoma and in patients who have isolated foci of high-grade intraepithelial neoplasia or mucosal cancer.
  • Limited resection with jejunal interposition provides an effective treatment option for patients who have early esophageal adenocarcinoma.
  • The onset of lymph node involvement is later in patients who have early adenocarcinoma than in patients who have squamous cell cancer, probably because chronic injury and repair mechanisms obliterate the otherwise abundant lymph vessels.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972568.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


41. Chandrasoma P, Wijetunge S, Demeester SR, Hagen J, Demeester TR: The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol; 2010 Nov;34(11):1574-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had oxyntocardiac±cardiac±intestinal epithelia between the squamous epithelium proximally and the proximal limit of gastric oxyntic mucosa distally were defined as having a squamo-oxyntic gap.
  • Only oxyntocardiac epithelium was seen in 190 (11.5%) of the patients, oxyntocardiac and cardiac epithelia in 898 (54.3%), and intestinal metaplasia in addition to the other 2 epithelial types in 567 (34.2%).
  • The prevalence of intestinal metaplasia was directly proportional to length of the squamo-oxyntic gap, being 24.3% (340/1399) when the length was <1 cm, and 83.5% (147/176) with length 1 to 5 cm.
  • All patients with a length more than 5 cm had intestinal metaplasia.
  • The distribution of the 3 epithelia was constant irrespective of the length of the squamocolumnar gap; intestinal metaplasia, when present, was seen maximally in the proximal region of the gap, cardiac epithelium intermediate and oxyntocardiac epithelium in the most distal segment of the gap.
  • Distal gastric biopsies showed no evidence of significant inflammation, intestinal metaplasia or Helicobacter pylori infection in 1543 (93.2%) of the patients, indicating that the squamo-oxyntic gap was largely independent of gastric pathology.
  • The presence of intestinal metaplasia within the squamo-oxyntic gap is the most accurate risk indicator for esophageal adenocarcinoma and defines Barrett esophagus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Epithelial Cells / pathology. Esophageal Neoplasms / diagnosis. Esophagus / pathology. Gastroesophageal Reflux / diagnosis. Parietal Cells, Gastric / pathology. Precancerous Conditions / diagnosis
  • [MeSH-minor] Biopsy. California. Endoscopy, Gastrointestinal. Humans. Metaplasia. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Severity of Illness Index

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 May;35(5):773; author reply 773-4 [21502913.001]
  • (PMID = 20871393.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. di Pietro M, Fitzgerald RC: Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet; 2009 Aug;126(2):233-46
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic gastro-oesophageal reflux disease can induce a metaplastic change of the distal oesophagus called Barrett's oesophagus whereby the normal squamous epithelium is substituted by a columnar epithelium.
  • Patients with Barrett's oesophagus are at increased risk of oesophageal adenocarcinoma which occurs through dysplastic stages with increasing degree of cellular and architectural disorganization.
  • Here, we review the knowledge acquired so far on the genetic and molecular alterations along the oesophageal metaplasia-dysplasia-carcinoma sequence.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics
  • [MeSH-minor] Carcinoma / diagnosis. Carcinoma / genetics. Cell Transformation, Neoplastic. Endoscopy / methods. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Humans. Male. Medical Oncology / methods. Metaplasia. Models, Biological. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365640.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 220
  •  go-up   go-down


43. Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto Y: Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. World J Surg; 2010 Jun;34(6):1265-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Turin proposal provides more specific criteria for the diagnosis of PDTC.
  • According to multivariate analysis, histological features of STI >or=10% and squamous metaplasia were significantly related to cause-specific survival, but scirrhous infiltration, necrosis, nuclear atypia, and vascular invasion were not.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953247.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9679TC07X4 / Iodine
  •  go-up   go-down


44. Chang D, Wang TY, Wei JC, Song JX, Jiao GG: [Surgical treatment of primary esophageal adenocarcinoma]. Zhonghua Wai Ke Za Zhi; 2007 May 15;45(10):681-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of primary esophageal adenocarcinoma].
  • OBJECTIVE: To summarize the surgical treatment and clinical bio-characteristics of primary esophageal adenocarcinoma (PEAC).
  • Twelve cases (27.9%) were in the middle 1/3 of esophagus, thirty-one cases (72.1%) in the lower 1/3, which were significantly different from esophageal squamous cell carcinoma (ESCC).
  • Fourteen cases were pure esophageal adenocarcinoma (32.6%), twenty-nine cases were adenosquamous cell carcinoma and adenoacanthoma cell carcinoma (67.4%).
  • CONCLUSIONS: Compared with ESCC, PEAC, mainly located in the inferior 1/3 of esophagus, is a malignant disease with higher frequency of lymph node metastasis and poor prognosis.
  • Early diagnosis and early treatment as well as curative operation could improve prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688820.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Talvensaari-Mattila A, Soini Y, Santala M: VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol; 2005 Mar-Apr;26(2):81-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The series consisted of 115 endometrioid endometrial adenocarcinoma patients with FIGO stage I-IV.
  • Additionally, samples from 3 patients with adenoacanthoma and 12 patients with poor prognostic variants of endometrial carcinoma were examined.
  • The median follow-up time of patients with endometrioid endometrial adenocarcinoma was 87 months.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15867479.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


46. Zeng Q, Zhang HP, Liu XS, Zhong N: [The role of biomarkers CK7, Vim and P53 in the development of subtypes of endometrial carcinoma]. Beijing Da Xue Xue Bao; 2005 Feb 18;37(1):81-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Biomarkers CK7, Vim, and P53 were immunohistochemistry-stained among 131 endometrial carcinoma specimens including 93 endometroid, 8 adenoacanthoma, and 32 rare subtypes of adenosquamas carcinoma, clean cell carcinoma, and papillary carcinoma, which had been confirmed clinically and pathologically, and studied statistically with Fisher test and Cochran-Mantel-Haenszel (CMH) Test.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719049.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-7; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


47. Kamaté B, Traoré CB, Diallo D, Sacko R, Toure M, Keita B, Teguete B, Traore Y, Diarra MH, Ouattara AT, Traoré AC, Mariko H, Dembele Y, Togola B, Tall K, Sanogo A, Diané M, Kaloga I, Traoré M, Dolo AI, Bayo S: [Extension of cervix cancer screening by visual methods to the community health centres in the district of Bamako]. Mali Med; 2008;23(4):29-33
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At all 177 biopsies were done, and histological diagnosis were: 67 dysplasias, 3 early invasive carcinomas, 69 invasive carcinomas and 38 inflammatory metaplasic lesions or nonconclusives aspects.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Community Health Centers / organization & administration. Mass Screening / organization & administration. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Acetic Acid. Adult. Biopsy. Coloring Agents. Female. Health Services Accessibility. Hospitals, University / organization & administration. Hospitals, University / statistics & numerical data. Humans. Iodides. Mali / epidemiology. Metaplasia. Middle Aged. Physical Examination. Prospective Studies. Staining and Labeling. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Dysplasia / epidemiology. Uterine Cervicitis / diagnosis. Uterine Cervicitis / epidemiology


48. Chlumská A, Boudová L, Benes Z, Zámecník M: Histopathologic changes in gastroesophageal reflux disease. A study of 126 bioptic and autoptic cases. Cesk Patol; 2007 Oct;43(4):142-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic diagnosis of reflux esophagitis is still complicated by the lack of a consensus opinion on what is the normal mucosa in the area of the gastroesophageal junction (GEJ).
  • Most authors consider GEJ as the junction between the squamous and the cardiac epithelium.
  • In 17 cases, CM displayed intestinal metaplasia (IM) predominantly of incomplete type and no dysplasia.
  • In one specimen of esophagus resected for adenocarcinoma, CM with incomplete IM was found in the vicinity of the tumor.
  • Squamous metaplastic epithelium was often seen near the orifices of submucosal esophageal glands in these areas, indicating the metaplastic nature of the glandular mucosa in the distal esophagus.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188921.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


49. Gabrecht T, Glanzmann T, Freitag L, Weber BC, van den Bergh H, Wagnières G: Optimized autofluorescence bronchoscopy using additional backscattered red light. J Biomed Opt; 2007 Nov-Dec;12(6):064016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchoscopy / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Bronchi / pathology. Bronchoscopes. Carcinoma in Situ / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Fluorescence. Humans. Image Processing, Computer-Assisted. Light. Lung Neoplasms / diagnosis. Metaplasia / diagnosis. Predictive Value of Tests. Scattering, Radiation. Spectrometry, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163832.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Rauf F, Kiyani N, Bhurgri Y: Metaplastic carcinoma of the breast, an intriguing rarity. Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):667-71
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metaplastic carcinoma breast is categorized as a rare heterogenous neoplasm generally characterized by a mixture of adenocarcinoma with dominant areas of spindle cell, squamous and/or other mesenchymal differentiation.
  • Twenty-four patients were identified with a mean age at diagnosis of 46.4 (+/-SD 3.8) years, and an age range of 28-68 years.
  • Component sub-categorization showed 13 (54.2%) cases of infiltrating ductal carcinoma with squamous metaplasia, followed by 2 (8.3 %) cases with heterologous elements, 4 (16.7%) cases with spindle cell component, 2 cases of matrix producing carcinoma and one case of squamous cell carcinoma.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Lymphatic Metastasis. Metaplasia. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250450.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


51. di Pietro M, Peters CJ, Fitzgerald RC: Clinical puzzle: Barrett's oesophagus. Dis Model Mech; 2008 Jul-Aug;1(1):26-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of oesophageal adenocarcinoma has increased dramatically in the Western world over the past two decades.
  • Owing to its dismal 5-year prognosis in advanced stages, early diagnosis is required in order to improve survival rates.
  • Barrett's is defined as the substitution of the normal stratified squamous epithelium of the oesophagus with a columnar cell lining with intestinal-type differentiation; a phenomenon commonly referred to as intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers / analysis. Cell Transformation, Neoplastic. Disease Progression. Early Diagnosis. Genetic Predisposition to Disease. Humans. Models, Biological

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Dec;129(6):2125-6; author reply 2126 [16344087.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):735-42 [16556175.001]
  • [Cites] Gut. 2006 Aug;55(8):1078-83 [16469795.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):423-31 [17064856.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Histopathology. 2007 Jun;50(7):920-7 [17543082.001]
  • [Cites] Gut. 2007 Jul;56(7):906-17 [17185354.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2788-803 [17974918.001]
  • [Cites] Gut. 2008 Feb;57(2):167-72 [17965067.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):89-94 [10767821.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Endoscopy. 2001 May;33(5):391-400 [11396755.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jul;22(1):1-6 [12103364.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):60-6 [12109857.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):457-9 [8781742.001]
  • [Cites] Br J Clin Pract. 1996 Jul-Aug;50(5):245-8 [8794600.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jan;34(1):46-52 [9542635.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):730-9 [15971196.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):889-907 [16338648.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • (PMID = 19048049.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2561971
  •  go-up   go-down


52. Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, Martin IG, Forman D: Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev; 2007 Oct;16(10):2090-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased mortality risks were also found for malignant neoplasms of the esophagus (SMR, 7.26; 95% CI, 3.87-12.42) and diseases of the digestive system (SMR, 2.03; 95% CI, 1.11-3.40).
  • Circulatory disease mortality was borderline statistically significant (SMR, 1.24; 95% CI, 1.00-1.52; P = 0.053) for those with a specialized intestinal metaplasia diagnosis of BE.
  • It has also shown that those who have a histologic BE diagnosis may also have an increased risk of circulatory disease mortality.
  • [MeSH-major] Adenocarcinoma / mortality. Barrett Esophagus / mortality. Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Neoplasms, Multiple Primary / mortality. Precancerous Conditions / mortality

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890521.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • 93.33% of cases exhibited a poorly differentiated squamous component and 66.66% of cases exhibited a well differentiated glandular component.
  • Squamous intraepithelial lesions in overlying epithelium was observed in 4 cases (26.66%).
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • Although, we registered a degree of variability in grading of the two components, with a tendency of squamous component toward poorly differentiated aspect and a slightly dominant aspect of well differentiated glandular pattern.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607797.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


54. Yubin L, Chihua F, Zhixiang J, Jinrui O, Zixian L, Jianghua Z, Ye L, Haosheng J, Chaomin L: Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol; 2008 Aug;15(8):2113-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Factors correlating with shorter survival were positive excision margin, metastasis, adenoacanthoma-type tumor, poor or unknown histological differentiation, and positive lymph nodes.
  • Positive excision margins, metastases, adenoacanthoma-type tumor, poor or unknown histological differentiation, and positive lymph nodes correlate with shorter survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546046.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Fine SW, Chan TY, Epstein JI: Inverted papillomas of the prostatic urethra. Am J Surg Pathol; 2006 Aug;30(8):975-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining cases showed foci of squamous metaplasia with moderate atypia (n = 4), rare true papillary fronds in a classic inverted papilloma background (n = 2), or both (n = 1).
  • Eleven cases with prostatic tissue revealed adenocarcinoma of the prostate [n = 6; Gleason score 6 (n = 3) or 7 (n = 3)], high-grade prostatic intraepithelial neoplasia (n = 1), benign prostatic hypertrophy (n = 3), or adenosis (n = 1).
  • No patients had a prior history of either inverted papilloma or urothelial carcinoma, whereas 2 patients were diagnosed with high-grade urothelial carcinoma of the bladder synchronous with their inverted papilloma diagnosis.
  • Although urothelial carcinoma elsewhere in the genitourinary tract may occur simultaneously, malignant transformation or recurrence as a malignant lesion has not been identified in inverted papilloma of the prostatic urethra.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Humans. Incidental Findings. Male. Middle Aged. Neoplasms, Multiple Primary / pathology. Prognosis. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861968.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kostova P, Chakalova G, Gancheva A: [Therapeutic results in patients with endometrial cancer]. Akush Ginekol (Sofiia); 2009;48(4):17-22
MedlinePlus Health Information. consumer health - Hormones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Predominate the patients with first stage cancer 117 (77%) and with endometroid adenocarcinoma/adenoacantoma 116 (76.3%), as well as these who were treated with surgery 134 (88.2%), followed by radio, hormonotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Hormones / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198781.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


57. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Meltzer SJ: Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res; 2007 Nov 1;13(21):6293-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: TAC1 hypermethylation in tissue samples showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P < 0.0001).
  • Both frequencies and normalized methylation values of TAC1 tissue methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's esophagus, EAC, and ESCC than in normal esophagus (P < 0.01).
  • The frequency of TAC1 hypermethylation increased dramatically and early during neoplastic progression, from 7.5% in normal esophagus to 55.6% in BE from patients with Barrett's metaplasia alone, 57.5% in dysplastic Barrett's esophagus, and 61.2% in EAC.
  • Circulating methylated TAC1 promoter DNA also offers potential as a biomarker for the diagnosis of EAC.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975140.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK067872; United States / NCI NIH HHS / CA / CA001808; United States / NCI NIH HHS / CA / CA085069; United States / NCI NIH HHS / CA / CA106763
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Tachykinins; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down






Advertisement